- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Transthyretin amyloid cardiomyopathy
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 935KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 247KB)
Tafamidis – July 2023
Tafamidis: Capsule 61 mg; Vyndamax®
Last updated
27 October 2023